Kornimate/medical-research-clean huggingface dataset:
value-based cognitive behavioral therapy for prevention of chronic whiplash-associated disorders

Conditions: Musculoskeletal Disorders; Whiplash

Summary: the purpose of this study is to determine whether a specifically tailored value-based cognitive behavioural therapy program (v-cbt) is able to prevent the development of persistent disability, pain, and psychological distress if delivered within the first three months after a whiplash injury.

the primary objective of the present study is to test whether a specifically tailored value-based cognitive-behavioural therapy program (v-cbt) is able to prevent the development of persistent disability, pain, and psychological distress if delivered within the first three months after a whiplash injury. methods. the current study is a two-armed randomized controlled study with a crossover design. group a is scheduled for v-cbt within one week of randomization and group b with a delayed onset 3 months after randomization.

Eligibility criteria:
* 18 and 65-years-old * wad level i-ii. * 3-months post-injury * disability in at least one important life domain (≥ 5 on the pain disability index) and moderate levels of pain (average pain intensity ≥ 4 on the nrs scale). * meet at least one of the psychological risk criteria: * elevated levels of pain catastrophizing, fear-avoidance-beliefs, symptoms of anxiety and/or depression, and posttraumatic stress symptoms.

Keywords: whiplash, prevention, pain, cognitive-behavioural therapy
a phase iv study to assess the safety of eupentatm inj

Conditions: Hepatitis B; Diphtheria; Haemophilus Influenzae Type B Infection; Tetanus; Pertussis

Summary: a prospective, open-label, interventional phase iv study to assess the safety of eupentatm inj.{fully liquid pentavalent vaccine, adsorbed diphtheria-tetanus-whole-cell pertussis-hepatitis b (rdna \[recombinant-deoxyribonucleic acid\])-haemophilus influenzae type b conjugate vaccine}


Eligibility criteria:
inclusion criteria: 1. written informed consent obtained from the parents or legally acceptable representatives (lars) of the subject who have been informed of the purpose, method, effects, etc., of the study 2. a male or female 6 to 8 weeks of age, inclusive, at the time of the first vaccination 3. in good health as determined by medical history, physical examination, and judgment by the investigator 4. body weight 3.2 kg and over at the time of screening 5. subjects for whom the investigator believed that their parent(s)/lar(s) could comply with the requirements of the protocol (e.g., completion of the subject diary cards, return for site visits) exclusion criteria: 1. past or present medical history of known or suspected diphtheria, tetanus, pertussis, polio, hb and/or hib diseases 2. any history of allergy to any of the components or excipients of eupentatm inj., including aluminum hydroxide, sodium hydrogen phosphate heptahydrate, monobasic sodium phosphate dihydrate, polysorbate and thimerosal 3. any medical condition which can compromise the infant's safety, as per investigator's discretion 4. history of seizures or abnormal cerebral signs in the newborn period or other serious neurological abnormality 5. history of bleeding tendencies 6. household contact and/or intimate exposure with a confirmed case of diphtheria, pertussis, hb, polio and/or hib diseases within in 30 days prior to screening 7. history of fever ≥ 38°c/ 100.4°f within 3 days prior to screening and/or intake of anti-pyretic/analgesic medication. subjects who meet this criterion will be rescreened to check the temperature after the temporary condition has resolved and if they are within the window period for age of first vaccination at the time of re-scheduled visit 8. history of previous diphtheria-tetanus-pertussis (dtp), and/or hib vaccination doses 9. history of previous or concurrent vaccinations other than bacillus calmette-guérin (bcg), hb vaccination at birth, polio, rotavirus and pneumococcal vaccines 10. known or suspected immune disorders, or, received immunosuppressive therapy 11. participation 30 days prior to screening in the study or simultaneously in another study and/or received any investigational product
the personalized chinese herb formulas over hypertensive bradyarrhythmia

Conditions: Hypertensive Heart Disease

Summary: 72 patients who have been diagnosed with hypertensive bradyarrhythmia were selected and randomly divided into research group and control group. the research group received regular medication against hypertension and the personalized formulas based on syndrome differentiation, meanwhile the control group only received the regular medication. the five symptoms (palpitation, short of breath, angina, dizzy and lumbar debility) were graded and used for evaluation of treatment.

to test the effect of chinese herb against the hypertensive heart disease, we designed this randomized controlled clinical trial. 72 patients who have been diagnosed with hypertensive bradyarrhythmia were selected and randomly divided into research group and control group. the five symptoms (palpitation, short of breath, angina, dizzy and lumbar debility) were graded. the research group received regular medication against hypertension and the personalized formulas based on syndrome differentiation, meanwhile the control group only received the regular medication. 2 weeks after treatment, all the symptoms were graded again.

Eligibility criteria:
inclusion criteria: \* clinical diagnosis of hypertensive bradyarhhythmia exclusion criteria: * with other elementary diseases * with pregnant * with receiving other treatment within past half year from the beginning of trial.
blood glucose differences using cgms between the left and right arm in patients with diabetes

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: there are multiple cgms that are fda approved. however, there are few studies looking at the variability of measurements between the left and right arm, and none looking at this effect in diabetic patients. this study may identify if glucose differences exist in the left and right arm in patients with type 1 or type 2 diabetes. furthermore, it may point to future directions for research to standardize methods of glucose measurement such as consistently measuring on only one side of the body.

the goal of this clinical trial is to determine the time-matched difference in glucose levels between the left arm and right arm in patients with type 1 or type 2 diabetes. the main objective aims to answer: • is there a difference in time-matched controlled glucose monitoring (cgm) - derived blood glucose between left and right arm in patients with type 1 or type 2 diabetes in target range (\ 180 mg/dl)? participants will wear two freestyle libre 3 sensors, 1 on the left and 1 on the right arm, continuously for 2 weeks. participants will need to download the freestyle libre 3 app on two separate mobile devices and connect the sensors with freestyle libre view accounts provided by the study team. the study team will collect and compare the data between the left and right arm for further analysis.

Eligibility criteria:
inclusion criteria: * adults 18-65 years of age * diagnosed with type 1 or type 2 diabetes * willing to wear cgms for 2 weeks on both arms * willing to attend 3 virtual calls meetings over the course of the trial * have active health insurance * willing to refrain from any heat therapy for the duration of the study * willing to refrain from consuming ascorbic acid and salicylic acid for the duration of the study due to known interaction with cgms * have access to 2 compatible mobile devices for the freestyle libre 3 cgms * not currently using any freestyle libre cgm * willing to provide hba1c readings within 3 months of the trial * have a baseline hba1c equal or above 6.5 exclusion criteria: * any active dermatologic condition on the upper arms * implanted medical devices including another continuous glucose monitoring device (i.e. pacemaker) * critically ill or dialysis patients * planned magnetic resonance imaging screening, computed tomography scan, x-ray imaging or high-frequency electrical heat treatment during study period * current systemic infections * subjects who are unable to fully understand the study or consent process will not be included in the study due to the lack of a qualified medical translator * refusal to sign the informed consent document * pregnant, planned pregnancy during study period, or currently breast-feeding * fear of needles to the point where patients cannot self-administer the sensors * history of allergic reactions or hypersensitivity from adhesives
role of placental invasion index in decision making of placenta accreta

Conditions: Placenta Accreta

Summary: this study will be conducted on women who have a diagnosis of placenta previ and using ultrasound to make the placenta invasion index and compare the accuracy of the diagnosis during the caesarean section whether it is accreta or not with determining the site and depth of invasion

this study will be conducted on women who have a diagnosis of placenta previ and using ultrasound to make the placenta invasion index and compare the accuracy of the diagnosis during the caesarean section whether it is accreta or not with determining the site and depth of invasion and whether there is injury occurred in the urinary system and determining the amount of blood transfusion and admission of intensive care, or whether the patient death

Eligibility criteria:
inclusion criteria: * all placenta previa and low laying placenta will be included exclusion criteria: * patient with sever attack
laryngeal vibro-tactile stimulation as a non-invasive symptomatic treatment for spasmodic dysphonia

Conditions: Adductor Spasmodic Dysphonia; Abductor Spastic Dysphonia; Laryngeal Dystonia

Summary: the general aim of the research is to provide scientific evidence that vibro-tactile stimulation (vts) represents a non-invasive form of neuromodulation that can induce measurable improvements in the speech of patients with laryngeal dystonia (ld) - also called spasmodic dysphonia (sd).


Eligibility criteria:
inclusion criteria: * 18 years of age or older * confirmed diagnosis of adductor or abductor ld for a minimum of 6 months. exclusion criteria: * regular intake of benzodiazepines * cognitive impairment: score \< 27 on the mini-mental state examination (mmse). * identify with a neurological or musculoskeletal impairment affecting speech motor function. these impairments may include a form of: dyskinesia, dystonia other than ld, essential tremor, huntington's disease, multiple system atrophy, muscle tension dysphonia, parkinsonism, progressive supranuclear palsy, spasticity, intracranial neoplasm (brain tumor), spinal neoplasm, cerebrovascular accident (stroke), mild traumatic brain injury, intracranial hemorrhage, multiple sclerosis. * non-english speaker. we will not enroll people who cannot speak english, because the voice assessment procedures (test sentences, cape_v clinical rating) have only been validated for english speakers at this point. * pregnant people. we will not enroll pregnant people as the device used in this study is investigational.

Keywords: adductor spasmodic dysphonia abductor spastic dysphonia laryngeal dystonia vibtro-tactile stimulation
remote limb ischemic conditioning to enhance learning and muscle strength in healthy young adults

Conditions: Healthy, Young Adults

Summary: the purpose of this research study is to determine if remote limb ischemic conditioning (rlic) can enhance learning of a motor (balance) and an ecologically valid, complex cognitive-motor (driving) task, and increase skeletal muscle strength in neurologically-intact young adults.

ischemic conditioning is an endogenous phenomenon in which exposing a target organ or tissue to one or more brief episodes of ischemia results in protection of that organ against subsequent ischemia. the effects of ischemic conditioning are not confined within an organ but can be can be transferred from one organ to another, a technique called remote ischemic conditioning. a clinically feasible method for this is remote limb ischemic conditioning (rlic), where episodes of ischemia and perfusion are induced with a blood pressure cuff placed on the arm. the overall goal of this line of work is to use ischemic conditioning to enhance learning and outcomes in persons with neurologic injuries. two previous studies have shown that remote limb ischemic conditioning (rlic) can enhance learning a motor task in healthy young adults. the current study extends that work to determine if rlic enhances muscle strength training and a complex cognitive-motor task (simulated driving). this phase i study will yield the necessary information to design and execute subsequent trials in neurologic patient populations.

Eligibility criteria:
inclusion criteria: 1. healthy adults between the age of 18 and 40 years 2. visual acuity of 20/20 with corrected vision exclusion criteria: 1. history of neurological condition (i.e. stroke, alzheimer's disease, parkinson's disease), attention deficit hyperactivity disorder (adhd), depression, bipolar disorder, balance impairment, or vestibular disorder 2. history of severe motion sickness, moderate to severe motion sickness or nausea on oculo-motor components of simulator sickness questionnaire, inability to ride a car, boat, train or airplane due to motion sickness 3. recent wrist, hand or forearm injury that would currently prevent ability to lift weights 4. history of lower extremity condition, injury, or surgery that would currently impair ability to stand or balance 5. any extremity soft tissue, orthopedic, or vascular injury (i.e. peripheral vascular disease) which may contraindicate rlic 6. any cognitive, sensory, or communication problem that would prevent completion of the study 7. history of or current sleep apnea 8. current intensive weight lifting or interval training exercise 9. current substance abuse or dependence 10. unwillingness to travel for all study visits

Keywords: ischemic conditioning, motor learning, strength, cognition
efficacy and safety of nnc-0156-0000-0009 during surgical procedures in subjects with haemophilia b

Conditions: Congenital Bleeding Disorder; Haemophilia B

Summary: this trial is conducted in africa, asia, europe and the united states of america (usa). the aim of the trial is to evaluate the safety and efficacy of nnc-0156-0000-0009 (nonacog beta pegol) during surgical procedures in patients with haemophilia b.


Eligibility criteria:
inclusion criteria: * patients with haemophilia b with a fix activity below or equal to 2% * male patients with moderately severe or severe congenital haemophilia b with a fix activity below or equal to 2% according to medical records * history of at least 150 exposure days to other fix products * scheduled major surgery exclusion criteria: * known history of fix (coagulation factor nine) inhibitors based on existing medical records, laboratory report reviews and patient and lar (legal acceptable representative) interviews * current fix (coagulation factor nine) inhibitors above or equal to 0.6 bethesda units (central laboratory) * previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records) * alt (alanine aminotransferase) 3 times the upper limit of normal reference ranges at screening (central laboratory) * immune modulating or chemotherapeutic medication
causes of fetal death: comparison of diagnostic accuracy between extensive and selective protocol testing

Conditions: Intrauterine Fetal Death

Summary: intrauterine fetal death (iufd) is defined as the occurrence of fetal death at \>20 weeks' gestation. iufd affects about 1 in 160 pregnancies (6-7 per 1000 births). optimal diagnostic evaluation for cases of iufd is generally based on extensive protocol testing i.e. maternal and fetal blood tests, fetal bacteriology, cytogenetic analysis, autopsy, and placental examination. this extensive protocol testing may vary in clinical practice and interpretation of the results is rarely performed by multidisciplinary staff to establish cause of death. these findings are related to the fact that there are very few epidemiological studies to validate optimal protocol, no french recommendations on this subject, and a relative lack of pathologists with expertise in perinatal pathology. only, one recent prospective study from the netherlands has concluded that extensive protocol testing should be redefined and some diagnostics tests may only be performed with suggestive clinical circumstances. however these recommendations may not be applicable to all populations and countries. to date, there are no french published series on iufd to evaluate causes of death in france and thereafter to better define optimal diagnostic evaluation tests. improvement in prenatal diagnosis in france may contribute to detection of the vast majority of severe chromosomal abnormalities and malformed fetuses and particularly those at risk of death. retrospective cohort unpublished data on iufd from lille and caen have reported exceptional deaths attributable to chromosomal or malformation abnormalities. in fact in these two series, most deaths were related to placental diseases or fetal growth retardation. the hypothesis is that extensive protocol testing is not helpful in clinical practice and selective protocol testing focused on specific risk situations can be as efficient.


Eligibility criteria:
inclusion criteria: * singleton fetus * intrauterine fetal death diagnosed antepartum * gestational age \> 22 weeks * woman informed * no women aged under 18 years exclusion criteria: * pregnancy termination * intrapartum death * person placed under judicial protection, guardianship
lonafarnib for patients with hutchinson-gilford progeria syndrome or progeroid laminopathy

Conditions: Progeria; HGPS

Summary: this treatment ind protocol will allow patients with hgps and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the hgps disease process resulting in improved outcomes (gordon et al, 2018). there are no approved treatments for hgps and progeroid laminopathies.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hgps or progeroid laminopathy by qualified medical doctor (based on common phenotype as described in gordon 2015 and merideth 2008). confirmation with genetic testing is preferred but not required. * adequate hepatic function as defined by sgpt (alt) and sgot (ast) ≤ 5 times upper limit of normal range for age exclusion criteria: * taking medications or foods that are known to be moderate or strong inducers or inhibitors of cyp3a4 or sensitive cyp3a substrates; or if a patient is taking one of these drugs and cannot safely discontinue or take an alternative drug, the dose of the inhibitor/inducer must be adjusted per the treating physician * taking digoxin, a p-gp substrate with a narrow therapeutic window. * severe renal impairment (gfr \< 30 ml/min/1.73m2). * uncontrolled infection. * presence of any active clinically relevant medical condition that in the opinion of the treating physician would preclude patient from safely participating in the program. * pregnant or breast-feeding or plan to become pregnant while on therapy.
the effect of ice, green tea and arnica montana application on post-operative intubation related sore throat and hoarseness

Conditions: Sore Throat; Hoarseness

Summary: the study was planned to determine the effect of arnica montana, green tea mouthwash and ice particles impregnation on postoperative sore throat and hoarseness.

research hypotheses hl: gargling with green tea after surgery reduces sore throat. h2: impregnation of postoperative ice particles reduces sore throat. h3: post-operative gargling with arnico montana reduces sore throat. h4: gargling with green tea after surgery reduces hoarseness. h5: impregnation of postoperative ice particles reduces hoarseness. h6: postoperative mouthwash with arnico montana reduces hoarseness. research question 1. do ice particles impregnation, gargling with green tea and gargling with arnico montana reduce intubation-related sore throat in patients undergoing general anesthesia? 2. do ice particles impregnation, gargling with green tea and gargling with arnico montana reduce hoarseness due to intubation in patients undergoing general anesthesia?

Eligibility criteria:
inclusion criteria: * to agree to participate in the research, * to be 18 years or older, * to know how to read and write, * no hearing problem, * not having difficulty in understanding, * to live before the operation, * having experience before surgery, * the duration of the operation is 30 minutes or more,7 * no nasogastric catheter exclusion criteria: * having a sore throat before surgery, * having hoarseness before surgery, * to have oral and neck surgery, * having a history of allergy, * having a nasogastric catheter, * the duration of the operation is less than 30 minutes,

Keywords: green tea arnico montana ice application endotracheal intubation sore throat nursing hoarseness
a pilot study for the treatment of iris neovascularization with macugen

Conditions: Iris Neovascularization; Diabetic Retinopathy

Summary: the purpose of this study is to determine if a drug called macugen may help to stop the growth of abnormal blood vessels on the iris that has occurred in the eye(s) as part of diabetic retinopathy.

diabetic retinopathy is an eye condition caused by diabetes in which new blood vessels grow on the retina (the back, inside part of the eye) and the iris. these vessels are not normal and may leak or break, causing bleeding in the eye. this process can lead to vision loss or blindness, glaucoma (disease of the eye where eye pressures are usually too high resulting in damage to the optic nerve), or other eye problems. this study is to determine if a drug called macugen may help to stop the growth of these abnormal blood vessels on the iris.

Eligibility criteria:
inclusion criteria: 1. male or female, at least 18 years of age 2. diabetic retinopathy with iris neovascularization 3. visual acuity must be light perception or better in the study eye 4. female patients of childbearing potential must have a negative urine pregnancy test at the screening visit. 5. written informed consent has been obtained 6. written authorization for use and release of health and research study information has been obtained exclusion criteria: 1. neovascular glaucoma ( a difficult form of glaucoma to control that leads to a painful eye with high intraocular pressure, corneal swelling, and "cell and flare" in the anterior chamber. caused by abnormal new blood vessel formation (neovascularization) on the iris, that extends over trabecular meshwork causing closure of angle drainage structures). 2. no light perception in the study eye. 3. inadequate view of retina for prp/angiography 4. anterior chamber intraocular lens implant 5. prp treatment in the past 60 days. patients may participate if the prp treatment is beyond 60 days and has newly diagnosed nvi or has nonregression of previously diagnosed nvi. 6. previous or current macugen use 7. any active ocular infection 8. any conditions which precludes patients ability to comply with study requirements including completion of the study 9. female patients who are pregnant, nursing, or planning pregnancy, or who are of childbearing potential and not using a reliable means of contraception 10. current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to screening 11. patient has a condition or is in a situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results or may interfere significantly with the patient's participation in the study

Keywords: vegf iris neovascularization diabetic retinopathy macugen